397 related articles for article (PubMed ID: 18587247)
1. Activation of PI3K is associated with reduced survival in renal cell carcinoma.
Merseburger AS; Hennenlotter J; Kuehs U; Simon P; Kruck S; Koch E; Stenzl A; Kuczyk MA
Urol Int; 2008; 80(4):372-7. PubMed ID: 18587247
[TBL] [Abstract][Full Text] [Related]
2. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.
Capodanno A; Camerini A; Orlandini C; Baldini E; Resta ML; Bevilacqua G; Collecchi P
Hum Pathol; 2009 Oct; 40(10):1408-17. PubMed ID: 19428048
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
[TBL] [Abstract][Full Text] [Related]
4. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
5. High Novel Oncogene with Kinase-Domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma.
Cao Q; Chen M; Li Z; Huang W; Jin Y; Ye X; Tong M
Clin Lab; 2016; 62(1-2):179-86. PubMed ID: 27012048
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
Minervini A; Di Cristofano C; Gacci M; Serni S; Menicagli M; Lanciotti M; Salinitri G; Rocca CD; Lapini A; Nesi G; Bevilacqua G; Minervini R; Carini M
J Urol; 2008 Oct; 180(4):1284-9. PubMed ID: 18707725
[TBL] [Abstract][Full Text] [Related]
7. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
[TBL] [Abstract][Full Text] [Related]
8. Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway.
Zhang H; Sheng L; Tao J; Chen R; Li Y; Sun Z; Qian W
Int J Oncol; 2016 Dec; 49(6):2498-2506. PubMed ID: 27779645
[TBL] [Abstract][Full Text] [Related]
9. PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival.
Rogers HA; Mayne C; Chapman RJ; Kilday JP; Coyle B; Grundy RG
Clin Cancer Res; 2013 Dec; 19(23):6450-60. PubMed ID: 24077346
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of PPAR-γ and PTEN in the renal cell carcinoma.
Zhu C; Wei J; Tian X; Li Y; Li X
Int J Clin Exp Pathol; 2015; 8(10):12668-77. PubMed ID: 26722456
[TBL] [Abstract][Full Text] [Related]
11. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.
Shih MC; Chen JY; Wu YC; Jan YH; Yang BM; Lu PJ; Cheng HC; Huang MS; Yang CJ; Hsiao M; Lai JM
Oncogene; 2012 May; 31(19):2389-400. PubMed ID: 21996732
[TBL] [Abstract][Full Text] [Related]
12. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
13. Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
Chun SH; Jung CK; Won HS; Kang JH; Kim YS; Kim MS
Head Neck; 2015 May; 37(5):636-43. PubMed ID: 24616007
[TBL] [Abstract][Full Text] [Related]
14. Limited prognostic value of tumor necrosis in patients with renal cell carcinoma.
Isbarn H; Patard JJ; Lughezzani G; Rioux-Leclercq N; Crépel M; Cindolo L; de la Taille A; Zini L; Villers A; Shariat SF; Bertini R; Karakiewicz PI
Urology; 2010 Jun; 75(6):1378-84. PubMed ID: 19781745
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
16. NOTCH1 functions as an oncogene by regulating the PTEN/PI3K/AKT pathway in clear cell renal cell carcinoma.
Liu S; Ma X; Ai Q; Huang Q; Shi T; Zhu M; Wang B; Zhang X
Urol Oncol; 2013 Aug; 31(6):938-48. PubMed ID: 21993533
[TBL] [Abstract][Full Text] [Related]
17. PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.
Wang LL; Hao S; Zhang S; Guo LJ; Hu CY; Zhang G; Gao B; Zhao JJ; Jiang Y; Tian WG; Wang J; Luo DL
Hum Pathol; 2017 Mar; 61():49-57. PubMed ID: 27864123
[TBL] [Abstract][Full Text] [Related]
18. Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer.
Al-Saad S; Donnem T; Al-Shibli K; Persson M; Bremnes RM; Busund LT
Anticancer Res; 2009 Oct; 29(10):4175-83. PubMed ID: 19846969
[TBL] [Abstract][Full Text] [Related]
19. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
[TBL] [Abstract][Full Text] [Related]
20. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
